A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Protocol: 
AAAR3758
Phase: 
III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Are you Eligible? (Inclusion Criteria)

1. Male or female, 18 years of age or older.
2. Has undergone 1 allo-HSCT from any donor (related or unrelated with any
degree of HLA matching) and any donor source (bone marrow, peripheral blood
stem cells, or cord blood) for a hematologic malignancy or disorder.
Recipients of myeloablative and reduced-intensity conditioning regimens are
eligible.
3. Be willing to avoid pregnancy or fathering children

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States